1 Bile Duct Cancer Drug Market Overview 1.1 Product Overview and Scope of Bile Duct Cancer Drug 1.2 Bile Duct Cancer Drug Segment by Type 1.2.1 Global Bile Duct Cancer Drug Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Cabozantinib S-malate 1.2.3 Elpamotide 1.2.4 Exatecan Mesylate 1.2.5 LY-2801653 1.2.6 NUC-1031 1.2.7 Others 1.3 Bile Duct Cancer Drug Segment by Application 1.3.1 Bile Duct Cancer Drug Sales Comparison by Application: (2021-2027) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Bile Duct Cancer Drug Market Size Estimates and Forecasts 1.4.1 Global Bile Duct Cancer Drug Revenue 2016-2027 1.4.2 Global Bile Duct Cancer Drug Sales 2016-2027 1.4.3 Bile Duct Cancer Drug Market Size by Region: 2016 Versus 2021 Versus 2027 2 Bile Duct Cancer Drug Market Competition by Manufacturers 2.1 Global Bile Duct Cancer Drug Sales Market Share by Manufacturers (2016-2021) 2.2 Global Bile Duct Cancer Drug Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Bile Duct Cancer Drug Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Bile Duct Cancer Drug Manufacturing Sites, Area Served, Product Type 2.5 Bile Duct Cancer Drug Market Competitive Situation and Trends 2.5.1 Bile Duct Cancer Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Bile Duct Cancer Drug Players Market Share by Revenue 2.5.3 Global Bile Duct Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Bile Duct Cancer Drug Retrospective Market Scenario by Region 3.1 Global Bile Duct Cancer Drug Retrospective Market Scenario in Revenue by Region: 2016-2021 3.2 Global Bile Duct Cancer Drug Retrospective Market Scenario in Sales by Region: 2016-2021 3.3 North America Bile Duct Cancer Drug Market Facts & Figures by Country 3.3.1 North America Bile Duct Cancer Drug Sales by Country 3.3.2 North America Bile Duct Cancer Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Bile Duct Cancer Drug Market Facts & Figures by Country 3.4.1 Europe Bile Duct Cancer Drug Sales by Country 3.4.2 Europe Bile Duct Cancer Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Bile Duct Cancer Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Bile Duct Cancer Drug Sales by Region 3.5.2 Asia Pacific Bile Duct Cancer Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Bile Duct Cancer Drug Market Facts & Figures by Country 3.6.1 Latin America Bile Duct Cancer Drug Sales by Country 3.6.2 Latin America Bile Duct Cancer Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Bile Duct Cancer Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Bile Duct Cancer Drug Sales by Country 3.7.2 Middle East and Africa Bile Duct Cancer Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Bile Duct Cancer Drug Historic Market Analysis by Type 4.1 Global Bile Duct Cancer Drug Sales Market Share by Type (2016-2021) 4.2 Global Bile Duct Cancer Drug Revenue Market Share by Type (2016-2021) 4.3 Global Bile Duct Cancer Drug Price by Type (2016-2021) 5 Global Bile Duct Cancer Drug Historic Market Analysis by Application 5.1 Global Bile Duct Cancer Drug Sales Market Share by Application (2016-2021) 5.2 Global Bile Duct Cancer Drug Revenue Market Share by Application (2016-2021) 5.3 Global Bile Duct Cancer Drug Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Ariad Pharmaceuticals, Inc. 6.1.1 Ariad Pharmaceuticals, Inc. Corporation Information 6.1.2 Ariad Pharmaceuticals, Inc. Description and Business Overview 6.1.3 Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Ariad Pharmaceuticals, Inc. Product Portfolio 6.1.5 Ariad Pharmaceuticals, Inc. Recent Developments/Updates 6.2 ArQule, Inc. 6.2.1 ArQule, Inc. Corporation Information 6.2.2 ArQule, Inc. Description and Business Overview 6.2.3 ArQule, Inc. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.2.4 ArQule, Inc. Product Portfolio 6.2.5 ArQule, Inc. Recent Developments/Updates 6.3 Array BioPharma Inc. 6.3.1 Array BioPharma Inc. Corporation Information 6.3.2 Array BioPharma Inc. Description and Business Overview 6.3.3 Array BioPharma Inc. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Array BioPharma Inc. Product Portfolio 6.3.5 Array BioPharma Inc. Recent Developments/Updates 6.4 Arrien Pharmaceuticals, LLC 6.4.1 Arrien Pharmaceuticals, LLC Corporation Information 6.4.2 Arrien Pharmaceuticals, LLC Description and Business Overview 6.4.3 Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Arrien Pharmaceuticals, LLC Product Portfolio 6.4.5 Arrien Pharmaceuticals, LLC Recent Developments/Updates 6.5 Aslan Pharmaceuticals Pte. Ltd. 6.5.1 Aslan Pharmaceuticals Pte. Ltd. Corporation Information 6.5.2 Aslan Pharmaceuticals Pte. Ltd. Description and Business Overview 6.5.3 Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Aslan Pharmaceuticals Pte. Ltd. Product Portfolio 6.5.5 Aslan Pharmaceuticals Pte. Ltd. Recent Developments/Updates 6.6 Bavarian Nordic A/S 6.6.1 Bavarian Nordic A/S Corporation Information 6.6.2 Bavarian Nordic A/S Description and Business Overview 6.6.3 Bavarian Nordic A/S Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Bavarian Nordic A/S Product Portfolio 6.6.5 Bavarian Nordic A/S Recent Developments/Updates 6.7 Bayer AG 6.6.1 Bayer AG Corporation Information 6.6.2 Bayer AG Description and Business Overview 6.6.3 Bayer AG Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Bayer AG Product Portfolio 6.7.5 Bayer AG Recent Developments/Updates 6.8 Blueprint Medicines Corporation 6.8.1 Blueprint Medicines Corporation Corporation Information 6.8.2 Blueprint Medicines Corporation Description and Business Overview 6.8.3 Blueprint Medicines Corporation Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Blueprint Medicines Corporation Product Portfolio 6.8.5 Blueprint Medicines Corporation Recent Developments/Updates 6.9 Boehringer Ingelheim GmbH 6.9.1 Boehringer Ingelheim GmbH Corporation Information 6.9.2 Boehringer Ingelheim GmbH Description and Business Overview 6.9.3 Boehringer Ingelheim GmbH Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Boehringer Ingelheim GmbH Product Portfolio 6.9.5 Boehringer Ingelheim GmbH Recent Developments/Updates 6.10 Boston Biomedical, Inc. 6.10.1 Boston Biomedical, Inc. Corporation Information 6.10.2 Boston Biomedical, Inc. Description and Business Overview 6.10.3 Boston Biomedical, Inc. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Boston Biomedical, Inc. Product Portfolio 6.10.5 Boston Biomedical, Inc. Recent Developments/Updates 6.11 Bristol-Myers Squibb Company 6.11.1 Bristol-Myers Squibb Company Corporation Information 6.11.2 Bristol-Myers Squibb Company Bile Duct Cancer Drug Description and Business Overview 6.11.3 Bristol-Myers Squibb Company Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Bristol-Myers Squibb Company Product Portfolio 6.11.5 Bristol-Myers Squibb Company Recent Developments/Updates 6.12 Celgene Corporation 6.12.1 Celgene Corporation Corporation Information 6.12.2 Celgene Corporation Bile Duct Cancer Drug Description and Business Overview 6.12.3 Celgene Corporation Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Celgene Corporation Product Portfolio 6.12.5 Celgene Corporation Recent Developments/Updates 6.13 CellAct Pharma GmbH 6.13.1 CellAct Pharma GmbH Corporation Information 6.13.2 CellAct Pharma GmbH Bile Duct Cancer Drug Description and Business Overview 6.13.3 CellAct Pharma GmbH Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.13.4 CellAct Pharma GmbH Product Portfolio 6.13.5 CellAct Pharma GmbH Recent Developments/Updates 6.14 Cellceutix Corporation 6.14.1 Cellceutix Corporation Corporation Information 6.14.2 Cellceutix Corporation Bile Duct Cancer Drug Description and Business Overview 6.14.3 Cellceutix Corporation Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Cellceutix Corporation Product Portfolio 6.14.5 Cellceutix Corporation Recent Developments/Updates 6.15 Cellular Biomedicine Group, Inc. 6.15.1 Cellular Biomedicine Group, Inc. Corporation Information 6.15.2 Cellular Biomedicine Group, Inc. Bile Duct Cancer Drug Description and Business Overview 6.15.3 Cellular Biomedicine Group, Inc. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.15.4 Cellular Biomedicine Group, Inc. Product Portfolio 6.15.5 Cellular Biomedicine Group, Inc. Recent Developments/Updates 6.16 Concordia Healthcare Corp. 6.16.1 Concordia Healthcare Corp. Corporation Information 6.16.2 Concordia Healthcare Corp. Bile Duct Cancer Drug Description and Business Overview 6.16.3 Concordia Healthcare Corp. Bile Duct Cancer Drug Sales, Revenue and Gross Margin (2016-2021) 6.16.4 Concordia Healthcare Corp. Product Portfolio 6.16.5 Concordia Healthcare Corp. Recent Developments/Updates 7 Bile Duct Cancer Drug Manufacturing Cost Analysis 7.1 Bile Duct Cancer Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Bile Duct Cancer Drug 7.4 Bile Duct Cancer Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Bile Duct Cancer Drug Distributors List 8.3 Bile Duct Cancer Drug Customers 9 Bile Duct Cancer Drug Market Dynamics 9.1 Bile Duct Cancer Drug Industry Trends 9.2 Bile Duct Cancer Drug Growth Drivers 9.3 Bile Duct Cancer Drug Market Challenges 9.4 Bile Duct Cancer Drug Market Restraints 10 Global Market Forecast 10.1 Bile Duct Cancer Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Bile Duct Cancer Drug by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Bile Duct Cancer Drug by Type (2022-2027) 10.2 Bile Duct Cancer Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Bile Duct Cancer Drug by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Bile Duct Cancer Drug by Application (2022-2027) 10.3 Bile Duct Cancer Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Bile Duct Cancer Drug by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Bile Duct Cancer Drug by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Bile Duct Cancer Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027) Table 2. Global Bile Duct Cancer Drug Sales (K Pcs) Comparison by Application (2021-2027) Table 3. Global Bile Duct Cancer Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Bile Duct Cancer Drug Covered in This Study Table 5. Global Bile Duct Cancer Drug Sales (K Pcs) of Key Manufacturers (2016-2021) Table 6. Global Bile Duct Cancer Drug Sales Share by Manufacturers (2016-2021) Table 7. Global Bile Duct Cancer Drug Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Bile Duct Cancer Drug Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Bile Duct Cancer Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021) Table 10. Manufacturers Bile Duct Cancer Drug Manufacturing Sites and Area Served Table 11. Manufacturers Bile Duct Cancer Drug Product Type Table 12. Global Bile Duct Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Bile Duct Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bile Duct Cancer Drug as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Bile Duct Cancer Drug Sales by Region (2016-2021) & (K Pcs) Table 16. Global Bile Duct Cancer Drug Sales Market Share by Region (2016-2021) Table 17. Global Bile Duct Cancer Drug Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Bile Duct Cancer Drug Sales by Country (2016-2021) & (K Pcs) Table 19. North America Bile Duct Cancer Drug Sales Market Share by Country (2016-2021) Table 20. North America Bile Duct Cancer Drug Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Bile Duct Cancer Drug Revenue Market Share by Country (2016-2021) Table 22. Europe Bile Duct Cancer Drug Sales by Country (2016-2021) & (K Pcs) Table 23. Europe Bile Duct Cancer Drug Sales Market Share by Country (2016-2021) Table 24. Europe Bile Duct Cancer Drug Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Bile Duct Cancer Drug Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Bile Duct Cancer Drug Sales by Region (2016-2021) & (K Pcs) Table 27. Asia Pacific Bile Duct Cancer Drug Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Bile Duct Cancer Drug Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Bile Duct Cancer Drug Revenue Market Share by Region (2016-2021) Table 30. Latin America Bile Duct Cancer Drug Sales by Country (2016-2021) & (K Pcs) Table 31. Latin America Bile Duct Cancer Drug Sales Market Share by Country (2016-2021) Table 32. Latin America Bile Duct Cancer Drug Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Bile Duct Cancer Drug Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Bile Duct Cancer Drug Sales by Country (2016-2021) & (K Pcs) Table 35. Middle East and Africa Bile Duct Cancer Drug Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Bile Duct Cancer Drug Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Bile Duct Cancer Drug Revenue Market Share by Country (2016-2021) Table 38. Global Bile Duct Cancer Drug Sales (K Pcs) by Type (2016-2021) Table 39. Global Bile Duct Cancer Drug Sales Market Share by Type (2016-2021) Table 40. Global Bile Duct Cancer Drug Revenue (Million US$) by Type (2016-2021) Table 41. Global Bile Duct Cancer Drug Revenue Share by Type (2016-2021) Table 42. Global Bile Duct Cancer Drug Price (USD/Pcs) by Type (2016-2021) Table 43. Global Bile Duct Cancer Drug Sales (K Pcs) by Application (2016-2021) Table 44. Global Bile Duct Cancer Drug Sales Market Share by Application (2016-2021) Table 45. Global Bile Duct Cancer Drug Revenue (Million US$) by Application (2016-2021) Table 46. Global Bile Duct Cancer Drug Revenue Share by Application (2016-2021) Table 47. Global Bile Duct Cancer Drug Price (USD/Pcs) by Application (2016-2021) Table 48. Ariad Pharmaceuticals, Inc. Corporation Information Table 49. Ariad Pharmaceuticals, Inc. Description and Business Overview Table 50. Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 51. Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Product Table 52. Ariad Pharmaceuticals, Inc. Recent Developments/Updates Table 53. ArQule, Inc. Corporation Information Table 54. ArQule, Inc. Description and Business Overview Table 55. ArQule, Inc. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 56. ArQule, Inc. Bile Duct Cancer Drug Product Table 57. ArQule, Inc. Recent Developments/Updates Table 58. Array BioPharma Inc. Corporation Information Table 59. Array BioPharma Inc. Description and Business Overview Table 60. Array BioPharma Inc. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 61. Array BioPharma Inc. Bile Duct Cancer Drug Product Table 62. Array BioPharma Inc. Recent Developments/Updates Table 63. Arrien Pharmaceuticals, LLC Corporation Information Table 64. Arrien Pharmaceuticals, LLC Description and Business Overview Table 65. Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 66. Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Product Table 67. Arrien Pharmaceuticals, LLC Recent Developments/Updates Table 68. Aslan Pharmaceuticals Pte. Ltd. Corporation Information Table 69. Aslan Pharmaceuticals Pte. Ltd. Description and Business Overview Table 70. Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 71. Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Product Table 72. Aslan Pharmaceuticals Pte. Ltd. Recent Developments/Updates Table 73. Bavarian Nordic A/S Corporation Information Table 74. Bavarian Nordic A/S Description and Business Overview Table 75. Bavarian Nordic A/S Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 76. Bavarian Nordic A/S Bile Duct Cancer Drug Product Table 77. Bavarian Nordic A/S Recent Developments/Updates Table 78. Bayer AG Corporation Information Table 79. Bayer AG Description and Business Overview Table 80. Bayer AG Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 81. Bayer AG Bile Duct Cancer Drug Product Table 82. Bayer AG Recent Developments/Updates Table 83. Blueprint Medicines Corporation Corporation Information Table 84. Blueprint Medicines Corporation Description and Business Overview Table 85. Blueprint Medicines Corporation Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 86. Blueprint Medicines Corporation Bile Duct Cancer Drug Product Table 87. Blueprint Medicines Corporation Recent Developments/Updates Table 88. Boehringer Ingelheim GmbH Corporation Information Table 89. Boehringer Ingelheim GmbH Description and Business Overview Table 90. Boehringer Ingelheim GmbH Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 91. Boehringer Ingelheim GmbH Bile Duct Cancer Drug Product Table 92. Boehringer Ingelheim GmbH Recent Developments/Updates Table 93. Boston Biomedical, Inc. Corporation Information Table 94. Boston Biomedical, Inc. Description and Business Overview Table 95. Boston Biomedical, Inc. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 96. Boston Biomedical, Inc. Bile Duct Cancer Drug Product Table 97. Boston Biomedical, Inc. Recent Developments/Updates Table 98. Bristol-Myers Squibb Company Corporation Information Table 99. Bristol-Myers Squibb Company Description and Business Overview Table 100. Bristol-Myers Squibb Company Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 101. Bristol-Myers Squibb Company Bile Duct Cancer Drug Product Table 102. Bristol-Myers Squibb Company Recent Developments/Updates Table 103. Celgene Corporation Corporation Information Table 104. Celgene Corporation Description and Business Overview Table 105. Celgene Corporation Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 106. Celgene Corporation Bile Duct Cancer Drug Product Table 107. Celgene Corporation Recent Developments/Updates Table 108. CellAct Pharma GmbH Corporation Information Table 109. CellAct Pharma GmbH Description and Business Overview Table 110. CellAct Pharma GmbH Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 111. CellAct Pharma GmbH Bile Duct Cancer Drug Product Table 112. CellAct Pharma GmbH Recent Developments/Updates Table 113. Cellceutix Corporation Corporation Information Table 114. Cellceutix Corporation Description and Business Overview Table 115. Cellceutix Corporation Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 116. Cellceutix Corporation Bile Duct Cancer Drug Product Table 117. Cellceutix Corporation Recent Developments/Updates Table 118. Cellular Biomedicine Group, Inc. Corporation Information Table 119. Cellular Biomedicine Group, Inc. Description and Business Overview Table 120. Cellular Biomedicine Group, Inc. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 121. Cellular Biomedicine Group, Inc. Bile Duct Cancer Drug Product Table 122. Cellular Biomedicine Group, Inc. Recent Developments/Updates Table 123. Concordia Healthcare Corp. Corporation Information Table 124. Concordia Healthcare Corp. Description and Business Overview Table 125. Concordia Healthcare Corp. Bile Duct Cancer Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 126. Concordia Healthcare Corp. Bile Duct Cancer Drug Product Table 127. Concordia Healthcare Corp. Recent Developments/Updates Table 128. Production Base and Market Concentration Rate of Raw Material Table 129. Key Suppliers of Raw Materials Table 130. Bile Duct Cancer Drug Distributors List Table 131. Bile Duct Cancer Drug Customers List Table 132. Bile Duct Cancer Drug Market Trends Table 133. Bile Duct Cancer Drug Growth Drivers Table 134. Bile Duct Cancer Drug Market Restraints Table 135. Global Bile Duct Cancer Drug Sales Forecast by Type (2022-2027) & (K Pcs) Table 136. Global Bile Duct Cancer Drug Sales Market Share Forecast by Type (2022-2027) Table 137. Global Bile Duct Cancer Drug Revenue Forecast by Type (2022-2027) & (US$ Million) Table 138. Global Bile Duct Cancer Drug Revenue Market Share Forecast by Type (2022-2027) Table 139. Global Bile Duct Cancer Drug Sales Forecast by Application (2022-2027) & (K Pcs) Table 140. Global Bile Duct Cancer Drug Sales Market Share Forecast by Application (2022-2027) Table 141. Global Bile Duct Cancer Drug Revenue Forecast by Application (2022-2027) & (US$ Million) Table 142. Global Bile Duct Cancer Drug Revenue Market Share Forecast by Application (2022-2027) Table 143. Global Bile Duct Cancer Drug Sales Forecast by Region (2022-2027) & (K Pcs) Table 144. Global Bile Duct Cancer Drug Sales Market Share Forecast by Region (2022-2027) Table 145. Global Bile Duct Cancer Drug Revenue Forecast by Region (2022-2027) & (US$ Million) Table 146. Global Bile Duct Cancer Drug Revenue Market Share Forecast by Region (2022-2027) Table 147. Research Programs/Design for This Report Table 148. Key Data Information from Secondary Sources Table 149. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Bile Duct Cancer Drug Figure 2. Global Bile Duct Cancer Drug Market Share by Type in 2020 & 2027 Figure 3. Cabozantinib S-malate Product Picture Figure 4. Elpamotide Product Picture Figure 5. Exatecan Mesylate Product Picture Figure 6. LY-2801653 Product Picture Figure 7. NUC-1031 Product Picture Figure 8. Others Product Picture Figure 9. Global Bile Duct Cancer Drug Market Share by Application in 2020 & 2027 Figure 10. Hospital Figure 11. Clinic Figure 12. Others Figure 13. Global Bile Duct Cancer Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global Bile Duct Cancer Drug Market Size 2016-2027 (US$ Million) Figure 15. Global Bile Duct Cancer Drug Sales 2016-2027 (K Pcs) Figure 16. Global Bile Duct Cancer Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 17. Bile Duct Cancer Drug Sales Share by Manufacturers in 2020 Figure 18. Global Bile Duct Cancer Drug Revenue Share by Manufacturers in 2020 Figure 19. The Global 5 and 10 Largest Bile Duct Cancer Drug Players: Market Share by Revenue in 2020 Figure 20. Bile Duct Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 21. Global Bile Duct Cancer Drug Sales Market Share by Region (2016-2021) Figure 22. Global Bile Duct Cancer Drug Sales Market Share by Region in 2020 Figure 23. Global Bile Duct Cancer Drug Revenue Market Share by Region (2016-2021) Figure 24. Global Bile Duct Cancer Drug Revenue Market Share by Region in 2020 Figure 25. U.S. Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Canada Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Germany Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. France Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. U.K. Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Italy Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Russia Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. China Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Japan Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. South Korea Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. India Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Australia Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Taiwan Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Indonesia Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Thailand Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Malaysia Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Philippines Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Vietnam Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Mexico Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Brazil Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Argentina Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Turkey Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Saudi Arabia Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. U.A.E Bile Duct Cancer Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. Sales Market Share of Bile Duct Cancer Drug by Type (2016-2021) Figure 50. Sales Market Share of Bile Duct Cancer Drug by Application (2016-2021) Figure 51. Sales Market Share of Bile Duct Cancer Drug by Application in 2020 Figure 52. Revenue Share of Bile Duct Cancer Drug by Application (2016-2021) Figure 53. Revenue Share of Bile Duct Cancer Drug by Application in 2020 Figure 54. Manufacturing Cost Structure of Bile Duct Cancer Drug Figure 55. Manufacturing Process Analysis of Bile Duct Cancer Drug Figure 56. Bile Duct Cancer Drug Industrial Chain Analysis Figure 57. Channels of Distribution Figure 58. Distributors Profiles Figure 59. Bottom-up and Top-down Approaches for This Report Figure 60. Data Triangulation Figure 61. Key Executives Interviewed

Ariad Pharmaceuticals, Inc. ArQule, Inc. Array BioPharma Inc. Arrien Pharmaceuticals, LLC Aslan Pharmaceuticals Pte. Ltd. Bavarian Nordic A/S Bayer AG Blueprint Medicines Corporation Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Celgene Corporation CellAct Pharma GmbH Cellceutix Corporation Cellular Biomedicine Group, Inc. Concordia Healthcare Corp.